Newsletter – End-Game Investment Category (Vol. 1, No. 7)

The World Class R&D InstituteEnd-Game+ (Investment Category+)

This month we finish our discussion of the investment categories with end-game: how we shut down research units that no longer have blockbuster+ potential. We argue that it pays well to end well. What you do to a research unit at the end is closely watched by all the other research units that are not ending. They’ll either applaud your actions or they’ll quickly look around for the emergency exit. You don’t get good research from insecure researchers. How you do end-game sets the stage for how well you’ll be able to do mid-game+.

October 2010 Home Page

subscribe iconhome page image thumb


This month’s home page topic is the End-Game investment category. You might ask why it’s even considered an investment category rather than a process for shutting down unsuccessful research units. The answer is we indeed will be investing into these units. End-game done well means we continue to invest into research units while they seek outside funding (should that be the path desired by unit management). Our ‘brand’ as a firm is we take care of research units regardless what Mother Nature throws their way.

We invest in end-game not with the intention of making money from these research units. We invest with the intention of making money from the other research units in progress or soon to come. How we do end-game redounds, significantly, on the success of other research units. It opens up the only way we have for non-destructively measuring interim progress in research units. We have no way as outsiders of truly assessing whether a research unit has hit a snag or will never succeed. True measures of progress depend on research management coming to the end-game conclusion on their own, which in turn depends on us doing end-game well.

There are many other reasons for doing end-game well. See the anchor article Why It Pays to End Well.

I’ll call your attention to one of this month's Editors’ Picks You Get the Answer You Want. Two researchers studying the same question came up with opposite answers. In a scientific bake-off they discovered that subtle differences in how they framed participant questions completely reversed the results. The article discusses why this is important for how we do clinical trials in the pharmaceutical industry.

Drop a line to let me know what you like or dislike about the website. It’s the only way we have of knowing how to advance the R&D agenda through the efforts of this Institute.

Keith Ortiz, President and CEO
The World Class R&D Institute, A Non-Profit Institution
609-954-8319 (c)

Browse Newsletter Summaries